Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to second-generation integrase inhibitor or protease inhibitor regimens for low-level viremia in HIV-infected patients
ChiCTR2300076417Phase 4Recruiting
- Sponsor
- Shanghai Public Health Clinical Center
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenofovir disoproxil fumarate, lamivudine and efavirenz in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS) (2 arms), sponsored by Shanghai Public Health Clinical Center. Primary endpoint: HIV viral load. Started Oct 2023; status: recruiting.
02
Drugs
tenofovir disoproxil fumaratelamivudineefavirenz
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on ChiCTR2300076417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076417.